Journal editor in chief who published controversial Covid papers resigns

Jose L. Domingo

The editor in chief of the journal Food and Chemical Toxicology (FCT) has resigned with more than a year left of his term, according to an email announcing his move to colleagues. 

In the email, first reproduced in Steve Kirsch’s Substack newsletter, the editor, Jose L. Domingo, cited “deep discrepancies” with the journal’s direction under publisher Elsevier as the reason for his early resignation. He shared the email with us when we reached out for comment. 

Domingo, a professor of toxicology and environmental Health at the Universitat Rovira i Virgili in Spain, listed three main points of contention: an agreement for the journal to publish documents for the Research Institute for Fragrance Materials, which Domingo believed to be a “drag” on the journal’s impact factor; FCT’s recent designation as the official journal of the Chinese Society of Toxicology; and a February editorial he wrote requesting submissions “on the potential toxic effects of COVID-19 vaccines.” 

He wrote: 

Continue reading Journal editor in chief who published controversial Covid papers resigns

How many ducks do you need to line up to get a publication retracted?

Mark Bolland

In July 2017, we notified the Journal of Bone and Mineral Metabolism (JBMM) of concerns about a randomized controlled trial (RCT) in rats which featured, among other problems, extensive duplication of data in a separate publication, large numbers of discrepancies in the methods and results between the publications, and serious concerns about the governance and conduct of the research.

The journal sought an explanation from the authors, Jun Iwamoto and Yoshihiro Sato, who currently have 119 retractions between them. The response avoided addressing most of the concerns and attributed all the discrepancies to minor errors, and was accepted by JBMM. 

In the intervening years, however, evidence about problems in the group’s work has mounted. And yet the paper remains neither retracted nor corrected. It has become just another in a long list of studies, along with ten others in the journal,  that we have beaten our heads against the wall to have journals fix.

Continue reading How many ducks do you need to line up to get a publication retracted?

Catch and kill: What it’s like to try to get a NEJM paper corrected

Marc Halushka

Last month,  the New England Journal of Medicine (NEJM) published a letter to the editor and a response reflecting a quite modest correction.  Essentially, the three letters “miR” will be removed from throughout a manuscript as the data, to date, do not support there being a human novel microRNA blood-based biomarker for myocarditis, as the original manuscript claimed.  

At the time of this posting, however, that change – which itself is well over a year in the making – has not yet occurred. And we really don’t understand why. This is our story of the arduous journey to improve the medical and scientific literature.

In May of 2021 the NEJM published “A novel circulating microRNA for the detection of acute myocarditis.” One of us (Marc Halushka), a practicing cardiovascular pathologist and microRNA researcher, recognized this paper was squarely in his wheelhouse.  The concept of a novel microRNA blood-based biomarker was exciting, but also curious. 

Continue reading Catch and kill: What it’s like to try to get a NEJM paper corrected

What happened when a psychology professor used a peer-reviewed paper to praise his own blog – and slam others’

Peter Kinderman via Wikimedia

A psychology professor has lost a paper for failing to disclose a crucial conflict of interest about one of the subjects of the work, which critiqued various blogs.

That’s because one of those blogs was written by none other than the author of the paper, Peter Kinderman, a professor at the University of Liverpool and a former president of the British Psychological Society. 

The paper’s comments about Kinderman’s Blog ‘F’ were generally positive, with phrases such as: 

Continue reading What happened when a psychology professor used a peer-reviewed paper to praise his own blog – and slam others’

In 1987, the NIH found a paper contained fake data. It was just retracted.

Ronald Reagan was president and James Wyngaarden was director of the National Institutes of Health when a division of the agency found 10 papers describing trials of psychiatric drugs it had funded had fake data or other serious issues. 

Thirty-five years later, one of those articles has finally been retracted. 

A 1987 report by the National Institute of Mental Health found that Stephen Breuning, then an assistant professor of child psychiatry at the University of Pittsburgh, had made up results in 10 papers purportedly describing research funded by two grants the institute had funded.

Russell Warne

The recent retraction came through the efforts of psychologist Russell Warne, who unearthed the report with the help of a couple librarians, posted it on his blog, and contacted journals about its findings. 

In a blog post about the report, Warne summed up the case: 

Continue reading In 1987, the NIH found a paper contained fake data. It was just retracted.

‘A big pain’: Professor up to six retractions for plagiarism and manipulated peer review

Bilal Afsar

A business professor has now had six papers retracted, resulting from a combination of plagiarism and manipulated peer review.

All six retractions for Bilal Afsar, an associate professor of management sciences at Hazara University in Pakistan, have come since last February. He is the only common author on all the papers, which were published in 2019 and 2020 – and in comments to Retraction Watch, blamed a research assistant whom he declined to name for the problems. 

The most recent paper to be retracted, in August of this year, was “Does thriving and trust in the leader explain the link between transformational leadership and innovative work behaviour? A cross-sectional survey.” It was originally published in the Journal of Research in Nursing in December of 2019 and has been cited 10 times, according to Clarivate’s Web of Science.

According to the retraction notice:

Continue reading ‘A big pain’: Professor up to six retractions for plagiarism and manipulated peer review

A grad student finds a ‘typo’ in a psychedelic study’s script that leads to a retraction

Paul Lodder

Sometime after it was published, Paul Lodder, a graduate student at the University of Amsterdam, had been trying without success to replicate the findings of a 2020 paper in Scientific Reports

The original article was written by a group led by Rubén Herzog, of the Universidad de Valparaíso in Chile. Titled “A mechanistic model of the neural entropy increase elicited by psychedelic drugs,” the paper purported to help illuminate what happens in the brain under the influence of substances like LSD. 

But the findings of the study wouldn’t replicate. And unlike some researchers who might blow off criticism of their work, or blame the replicators for the failure, Herzog sent Lodder the scripts his team had used.

Lodder found the problem quickly. As Herzog related to Retraction Watch, Lodder (whose schedule has been challenging the past few weeks as we’ve played phone tag) [See update on this post.]:

Continue reading A grad student finds a ‘typo’ in a psychedelic study’s script that leads to a retraction

Can you explain what these 1,500 papers are doing in this journal?

James Heathers


The Internet of Things. Computer science. Botany. COVID-19.

All worthwhile subjects, to be sure. But what do they have to do with materials science?

That’s what James Heathers, who will be familiar to readers of Retraction Watch as a “data thug,” found himself wondering after he spent a weekend looking into articles published by Materials Today: Proceedings. He found at least 1,500 off-topic papers, many with abstracts containing “tortured phrases” that may have been written by translation or paraphrasing software, and a few with titles that had been previously advertised with author positions for sale online. 

He detailed his findings in a blog post today, and says that the journal – an Elsevier title – has published many articles that look like the work of a paper mill.  

Continue reading Can you explain what these 1,500 papers are doing in this journal?

Dental school dean up to five retractions for cancer research papers

Russell Taichman

A dental school dean with a history of publishing cancer research papers is up to five retractions

Russell Taichman, the dean of the University of Alabama at Birmingham’s school of dentistry, lost two papers in Cancer Research earlier this month, after losing three others since 2020. Most of the retractions came after PubPeer comments about duplicated images in some of the papers. 

In April of 2020, Elisabeth Bik commented on two of Taichman’s papers that would later be retracted, pointing out potentially recycled images between the articles. 

None of the authors responded on PubPeer, but Taichman apparently took her comments to heart, and credited her in a retraction notice. 

Continue reading Dental school dean up to five retractions for cancer research papers

Journal says ivermectin study met standard for ‘credible science’

Flavio Cadegiani

A journal editor is defending his decision to publish a new paper showing that ivermectin can prevent Covid-19, despite more than a dozen retractions of such papers from the literature.

The article, “Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects,” appeared in Cureus August 31. 

The authors included Pierre Kory, a critical care specialist better known as the leader of the   Front-Line Covid-19 Critical Care Alliance, based in Madison, Wis.  Kory has been an active promoter of the use of ivermectin and other questionable remedies for  Covid-19 – even testifying before Congress about his ideas – although his most high-profile paper on the topic was retracted last November. 

Continue reading Journal says ivermectin study met standard for ‘credible science’